Adenosine inhibition of lipopolysaccharide-induced interleukin-6 secretion by the osteoblastic cell line MG-63

Joseph M. Russell, Graham S. Stephenson, Clare E Yellowley-genetos, Hilary P. Benton

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Adenosine is known to inhibit inflammatory responses in many cell systems via a family of purine receptors termed "P1." The P1 family consists of the adenosine receptors (ADORA) of subtypes A1, A2a, A2b, and A3. In order to assess whether adenosine has anti-inflammatory actions in osteoblastic cells, we investigated its effects on lipopolysaccharide (LPS)-induced interleukin 6 (IL-6) release in an in vitro inflammatory functional response model. We showed that the osteoblastic cell line MG-63 expresses ADORA1, A2a, and A2b but not A3. Treatment of MG-63 cells with adenosine and pharmacological ADORA agonist 5′-N-ethylcarboxamidoadenosine or 2-[4-(2-p-carboxyethyl) phenylamino]-5′-N-ethylcarboxamidoadenosine (CGS21680) inhibits LPS-induced IL-6 release. This inhibition was protein kinase A (PKA)-dependent and mimicked by treatment with the adenylate cyclase activator forskolin. Treatment of MG-63 with the ADORA2a-specific antagonist ZM241385 partially reversed the inhibitory effects of ADORA stimulation on LPS-induced IL-6 release. Overall, these data suggest that ADORA2a is involved in the regulation of LPS-induced IL-6 release, thus illustrating a regulatory role for adenosine receptors in the control of inflammation and potentially osteoclastogenesis and bone resorption.

Original languageEnglish (US)
Pages (from-to)316-326
Number of pages11
JournalCalcified Tissue International
Volume81
Issue number4
DOIs
StatePublished - Oct 2007

Fingerprint

Adenosine
Lipopolysaccharides
Interleukin-6
Adenosine-5'-(N-ethylcarboxamide)
Cell Line
Purinergic P1 Receptors
Purinergic Receptors
Colforsin
Bone Resorption
Cyclic AMP-Dependent Protein Kinases
Adenylyl Cyclases
Osteogenesis
Anti-Inflammatory Agents
Pharmacology
Inflammation

Keywords

  • Adenosine
  • Inflammation
  • Interleukin-6
  • Osteoblast
  • Purine receptor

ASJC Scopus subject areas

  • Endocrinology

Cite this

Adenosine inhibition of lipopolysaccharide-induced interleukin-6 secretion by the osteoblastic cell line MG-63. / Russell, Joseph M.; Stephenson, Graham S.; Yellowley-genetos, Clare E; Benton, Hilary P.

In: Calcified Tissue International, Vol. 81, No. 4, 10.2007, p. 316-326.

Research output: Contribution to journalArticle

@article{07434ee44f054e5da88b04e00d033b8e,
title = "Adenosine inhibition of lipopolysaccharide-induced interleukin-6 secretion by the osteoblastic cell line MG-63",
abstract = "Adenosine is known to inhibit inflammatory responses in many cell systems via a family of purine receptors termed {"}P1.{"} The P1 family consists of the adenosine receptors (ADORA) of subtypes A1, A2a, A2b, and A3. In order to assess whether adenosine has anti-inflammatory actions in osteoblastic cells, we investigated its effects on lipopolysaccharide (LPS)-induced interleukin 6 (IL-6) release in an in vitro inflammatory functional response model. We showed that the osteoblastic cell line MG-63 expresses ADORA1, A2a, and A2b but not A3. Treatment of MG-63 cells with adenosine and pharmacological ADORA agonist 5′-N-ethylcarboxamidoadenosine or 2-[4-(2-p-carboxyethyl) phenylamino]-5′-N-ethylcarboxamidoadenosine (CGS21680) inhibits LPS-induced IL-6 release. This inhibition was protein kinase A (PKA)-dependent and mimicked by treatment with the adenylate cyclase activator forskolin. Treatment of MG-63 with the ADORA2a-specific antagonist ZM241385 partially reversed the inhibitory effects of ADORA stimulation on LPS-induced IL-6 release. Overall, these data suggest that ADORA2a is involved in the regulation of LPS-induced IL-6 release, thus illustrating a regulatory role for adenosine receptors in the control of inflammation and potentially osteoclastogenesis and bone resorption.",
keywords = "Adenosine, Inflammation, Interleukin-6, Osteoblast, Purine receptor",
author = "Russell, {Joseph M.} and Stephenson, {Graham S.} and Yellowley-genetos, {Clare E} and Benton, {Hilary P.}",
year = "2007",
month = "10",
doi = "10.1007/s00223-007-9060-y",
language = "English (US)",
volume = "81",
pages = "316--326",
journal = "Calcified Tissue International",
issn = "0171-967X",
publisher = "Springer New York",
number = "4",

}

TY - JOUR

T1 - Adenosine inhibition of lipopolysaccharide-induced interleukin-6 secretion by the osteoblastic cell line MG-63

AU - Russell, Joseph M.

AU - Stephenson, Graham S.

AU - Yellowley-genetos, Clare E

AU - Benton, Hilary P.

PY - 2007/10

Y1 - 2007/10

N2 - Adenosine is known to inhibit inflammatory responses in many cell systems via a family of purine receptors termed "P1." The P1 family consists of the adenosine receptors (ADORA) of subtypes A1, A2a, A2b, and A3. In order to assess whether adenosine has anti-inflammatory actions in osteoblastic cells, we investigated its effects on lipopolysaccharide (LPS)-induced interleukin 6 (IL-6) release in an in vitro inflammatory functional response model. We showed that the osteoblastic cell line MG-63 expresses ADORA1, A2a, and A2b but not A3. Treatment of MG-63 cells with adenosine and pharmacological ADORA agonist 5′-N-ethylcarboxamidoadenosine or 2-[4-(2-p-carboxyethyl) phenylamino]-5′-N-ethylcarboxamidoadenosine (CGS21680) inhibits LPS-induced IL-6 release. This inhibition was protein kinase A (PKA)-dependent and mimicked by treatment with the adenylate cyclase activator forskolin. Treatment of MG-63 with the ADORA2a-specific antagonist ZM241385 partially reversed the inhibitory effects of ADORA stimulation on LPS-induced IL-6 release. Overall, these data suggest that ADORA2a is involved in the regulation of LPS-induced IL-6 release, thus illustrating a regulatory role for adenosine receptors in the control of inflammation and potentially osteoclastogenesis and bone resorption.

AB - Adenosine is known to inhibit inflammatory responses in many cell systems via a family of purine receptors termed "P1." The P1 family consists of the adenosine receptors (ADORA) of subtypes A1, A2a, A2b, and A3. In order to assess whether adenosine has anti-inflammatory actions in osteoblastic cells, we investigated its effects on lipopolysaccharide (LPS)-induced interleukin 6 (IL-6) release in an in vitro inflammatory functional response model. We showed that the osteoblastic cell line MG-63 expresses ADORA1, A2a, and A2b but not A3. Treatment of MG-63 cells with adenosine and pharmacological ADORA agonist 5′-N-ethylcarboxamidoadenosine or 2-[4-(2-p-carboxyethyl) phenylamino]-5′-N-ethylcarboxamidoadenosine (CGS21680) inhibits LPS-induced IL-6 release. This inhibition was protein kinase A (PKA)-dependent and mimicked by treatment with the adenylate cyclase activator forskolin. Treatment of MG-63 with the ADORA2a-specific antagonist ZM241385 partially reversed the inhibitory effects of ADORA stimulation on LPS-induced IL-6 release. Overall, these data suggest that ADORA2a is involved in the regulation of LPS-induced IL-6 release, thus illustrating a regulatory role for adenosine receptors in the control of inflammation and potentially osteoclastogenesis and bone resorption.

KW - Adenosine

KW - Inflammation

KW - Interleukin-6

KW - Osteoblast

KW - Purine receptor

UR - http://www.scopus.com/inward/record.url?scp=34848824403&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34848824403&partnerID=8YFLogxK

U2 - 10.1007/s00223-007-9060-y

DO - 10.1007/s00223-007-9060-y

M3 - Article

C2 - 17705048

AN - SCOPUS:34848824403

VL - 81

SP - 316

EP - 326

JO - Calcified Tissue International

JF - Calcified Tissue International

SN - 0171-967X

IS - 4

ER -